Lymphoma Diffuse Large B Cell clinical trials

Explore recruiting lymphoma diffuse large b cell clinical trials.

Recruiting lymphoma diffuse large b cell studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoma Diffuse Large B Cell trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CC-122 Rollover Study

France, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

France, Netherlands, Hungary, Czechia, Germany, Spain +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)

Spain, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine- Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).

Poland, Spain, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)

Norway, Sweden, Denmark, Finland, Italy, Estonia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lymphoma Diffuse Large B Cell trials by city

Lymphoma Diffuse Large B Cell clinical trials

Recruiting lymphoma diffuse large b cell studies right now

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

CAR-T Followed by Bispecific Antibodies

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

CR-CHOP+X in Previously Untreated DEL